Crinetics Pharmaceuticals will present a company update at the J.P. Morgan Healthcare Conference on January 14, 2025, discussing key priorities and milestones for 2025, including the potential approval of paltusotine for acromegaly and the development of atumelnant for congenital adrenal hyperplasia and Cushing's disease.